• +1-646-491-9876
    • +91-20-67278686

    Search

    Traumatic Brain Injury - Pipeline Review, H1 2017

    Traumatic Brain Injury - Pipeline Review, H1 2017

    • Report Code ID: RW0001689371
    • Category Healthcare
    • No. of Pages 259
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

    Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

    Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Traumatic Brain Injury - Overview 9
    Traumatic Brain Injury - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 16
    Products under Development by Companies 17
    Products under Development by Universities/Institutes 21
    Traumatic Brain Injury - Therapeutics Assessment 22
    Assessment by Target 22
    Assessment by Mechanism of Action 26
    Assessment by Route of Administration 30
    Assessment by Molecule Type 32
    Traumatic Brain Injury - Companies Involved in Therapeutics Development 34
    ALSP Inc 34
    Amarantus Bioscience Holdings Inc 34
    Apollo Endosurgery Inc 35
    Athersys Inc 35
    Beech Tree Labs Inc 36
    Cognosci Inc 36
    Eustralis Pharmaceuticals Ltd 37
    Intellect Neurosciences Inc 37
    International Stem Cell Corp 38
    Ischemix Inc 38
    Karyopharm Therapeutics Inc 39
    Kyorin Pharmaceutical Co Ltd 39
    Levolta Pharmaceuticals Inc 40
    Lixte Biotechnology Holdings Inc 40
    MandalMed Inc 41
    Mapreg SAS 41
    Neuralstem Inc 42
    Neuren Pharmaceuticals Ltd 42
    Neurofx Inc 43
    NeuroNascent Inc 43
    NeuroVive Pharmaceutical AB 44
    New World Laboratories Inc 44
    NuvOx Pharma LLC 45
    Omeros Corp 45
    Oxeia Biopharmaceuticals Inc 46
    PharmatrophiX Inc 46
    Phylogica Ltd 47
    Prevacus Inc 47
    QR Pharma Inc 48
    RegeneRx Biopharmaceuticals Inc 48
    Remedy Pharmaceuticals Inc 49
    Sage Therapeutics Inc 49
    SanBio Inc 50
    STATegics Inc 50
    Stemedica Cell Technologies Inc 51
    SynZyme Technologies LLC 51
    Tetra Discovery Partners LLC 52
    Thera Neuropharma Inc 52
    vasopharm GmbH 53
    VG Life Sciences Inc 53
    Traumatic Brain Injury - Drug Profiles 54
    (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 54
    2-DG - Drug Profile 55
    ALP-496 - Drug Profile 57
    AMRS-001 - Drug Profile 59
    AST-002 - Drug Profile 68
    AST-004 - Drug Profile 69
    AVL-8168 - Drug Profile 70
    BQ-A - Drug Profile 71
    brexanolone - Drug Profile 72
    BTL-slo - Drug Profile 81
    Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 83
    CEVA-101 - Drug Profile 84
    CEVA-102 - Drug Profile 86
    CHEC-9 - Drug Profile 87
    CMX-2043 - Drug Profile 88
    CNB-001 - Drug Profile 91
    COG-1410 - Drug Profile 93
    cyclosporine - Drug Profile 95
    dexamethasone acetate + melatonin - Drug Profile 101
    EPO-Variant - Drug Profile 102
    EUC-001 - Drug Profile 103
    felbamate - Drug Profile 104
    glyburide - Drug Profile 105
    HBI-002 - Drug Profile 109
    HBI-137 - Drug Profile 110
    HBN-1 - Drug Profile 111
    HBN-2 - Drug Profile 112
    HPI-201 - Drug Profile 113
    HPI-363 - Drug Profile 115
    ibudilast - Drug Profile 116
    ICCN-100 - Drug Profile 126
    ISC-hpNSC - Drug Profile 127
    JM-4 - Drug Profile 132
    KPT-350 - Drug Profile 133
    LB-201 - Drug Profile 135
    LB-205 - Drug Profile 136
    LM-22A4 - Drug Profile 137
    LM11A-31BHS - Drug Profile 139
    Lpathomab - Drug Profile 141
    MAP-4343 - Drug Profile 144
    Monoclonal Antibody for Central Nervous System - Drug Profile 145
    Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile 146
    Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 147
    MW-151 - Drug Profile 148
    N-acetyl cysteine amide - Drug Profile 149
    ND-478 - Drug Profile 150
    Neu-2000 - Drug Profile 151
    neuregulin-1 - Drug Profile 153
    NFx-101 - Drug Profile 154
    NNI-370 - Drug Profile 155
    NNZ-2591 - Drug Profile 156
    NSI-189 - Drug Profile 158
    NSI-566 - Drug Profile 163
    NVX-108 - Drug Profile 171
    NVX-428 - Drug Profile 172
    NWL-53 - Drug Profile 173
    NYX-2925 - Drug Profile 174
    OXE-103 - Drug Profile 176
    PEG-HCC - Drug Profile 177
    PF-05285401 - Drug Profile 178
    Posiphen - Drug Profile 189
    PRV-002 - Drug Profile 192
    PYC-35 - Drug Profile 193
    PYC-36 - Drug Profile 194
    PYC-38 - Drug Profile 195
    PYC-98 - Drug Profile 196
    R-554 - Drug Profile 197
    RGN-352 - Drug Profile 198
    ronopterin - Drug Profile 202
    SanFlow - Drug Profile 204
    SB-623 - Drug Profile 205
    Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 209
    Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 210
    Small Molecules for Traumatic Brain Injury - Drug Profile 211
    Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 212
    Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 213
    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 214
    Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 220
    STSE-15 - Drug Profile 221
    SYN-2 - Drug Profile 223
    SYN-NCE - Drug Profile 224
    T-094 - Drug Profile 225
    TauC-3 - Drug Profile 226
    UH-0113 - Drug Profile 228
    UH-0213 - Drug Profile 229
    VG-1177 - Drug Profile 230
    VitalHeme - Drug Profile 232
    VOLT-02 - Drug Profile 233
    XN-001 - Drug Profile 234
    ZL-006 - Drug Profile 235
    Traumatic Brain Injury - Dormant Projects 236
    Traumatic Brain Injury - Discontinued Products 239
    Traumatic Brain Injury - Product Development Milestones 240
    Featured News & Press Releases 240
    Appendix 252
    Methodology 252
    Coverage 252
    Secondary Research 252
    Primary Research 252
    Expert Panel Validation 252
    Contact Us 252
    Disclaimer 253

    List of Tables

    Number of Products under Development for Traumatic Brain Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2017
    Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2017
    Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2017
    Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2017
    Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
    Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2017
    Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2017
    Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
    Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2017
    Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2017
    Traumatic Brain Injury - Pipeline by Omeros Corp, H1 2017
    Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2017
    Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1 2017
    Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2017
    Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2017
    Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2017
    Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2017
    Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2017
    Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017
    Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2017
    Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2017
    Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1 2017
    Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2017
    Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2017
    Traumatic Brain Injury - Dormant Projects, H1 2017
    Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Traumatic Brain Injury - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Traumatic Brain Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    ALSP Inc
    Amarantus Bioscience Holdings Inc
    Apollo Endosurgery Inc
    Athersys Inc
    Beech Tree Labs Inc
    Cognosci Inc
    Eustralis Pharmaceuticals Ltd
    Intellect Neurosciences Inc
    International Stem Cell Corp
    Ischemix Inc
    Karyopharm Therapeutics Inc
    Kyorin Pharmaceutical Co Ltd
    Levolta Pharmaceuticals Inc
    Lixte Biotechnology Holdings Inc
    MandalMed Inc
    Mapreg SAS
    Neuralstem Inc
    Neuren Pharmaceuticals Ltd
    Neurofx Inc
    NeuroNascent Inc
    NeuroVive Pharmaceutical AB
    New World Laboratories Inc
    NuvOx Pharma LLC
    Omeros Corp
    Oxeia Biopharmaceuticals Inc
    PharmatrophiX Inc
    Phylogica Ltd
    Prevacus Inc
    QR Pharma Inc
    RegeneRx Biopharmaceuticals Inc
    Remedy Pharmaceuticals Inc
    Sage Therapeutics Inc
    SanBio Inc
    STATegics Inc
    Stemedica Cell Technologies Inc
    SynZyme Technologies LLC
    Tetra Discovery Partners LLC
    Thera Neuropharma Inc
    vasopharm GmbH
    VG Life Sciences Inc

    Request for Sample

    Report Url https://www.reportsweb.com//traumatic-brain-injury-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//traumatic-brain-injury-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//traumatic-brain-injury-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments